Pfizer Seeks New Homes For Assets Orphaned By R&D Reorg
This article was originally published in The Pink Sheet Daily
Executive Summary
New head of out-licensing takes on prospects cast off in Pfizer’s recent exit from non-“high priority” therapeutic areas.
You may also be interested in...
Pfizer Prunes Its Pipeline And Creates A Stockpile Of Compounds For Deals
Pfizer's latest pipeline refinement shows the drug maker is more than willing to stick with its professed "invest to win" core therapeutic areas after acquiring Wyeth, but the pharma giant is, nonetheless, hedging its bets by keeping some compounds from other areas for the sake of diversity
Pfizer Prunes Its Pipeline And Creates A Stockpile Of Compounds For Deals
Pfizer's latest pipeline refinement shows the drug maker is more than willing to stick with its professed "invest to win" core therapeutic areas after acquiring Wyeth, but the pharma giant is, nonetheless, hedging its bets by keeping some compounds from other areas for the sake of diversity
Pfizer Halts Phase III Study Of Sutent In Advanced Breast Cancer
Failed single-agent trial is small setback for Sutent, analyst says. Pfizer has three combination trials also ongoing in breast cancer settings.